CellX, a biotechnology company in China and Tofflon, a pharmacutical equipment supplier, have announced a strategic partnership to create China’s first cultivated meat production facility. This facility will provide CellX the ability to increase scale of its suspension cell lines in serum-free media at thousand-litre sacle. Included in the announcement was the company’s intention to create cellular agriculture facilities world-wide, enabling the scalability of cultivated meat.
By combining the expertise of CellX in cellular agriculture with Tofflon’s experience with biological equipment and production capacity, the partnership will work towards the goal of creating a future that’s sustainable for all.
China’s first cultivated meat pilot facility is due for completion by the end of 2023.
CellX is a cellular agriculture company based in Shanghai, working to bring cultivated meat products to consumers in China and around the world. Its goal is to provide a sustainable source of animal protein, better health for all human beings, and improved animal welfare. Founded in 2020, CellX has built a top R&D team of 40 and raised $15M+. The team focuses on building platform technologies with a multi-species approach.
More information at www.cellx.cn
Tofflon (Stock Code: SZ 300171) was founded in 1993 and listed on the China Shenzhen Stock Exchange in 2011. Based in Shanghai, Tofflon provides process support, core equipment, consumables, and system engineering solutions for global drug and food manufacturing. Focusing on the study of drug manufacturing science and integrating knowledge of drug processes and pharma equipment, Tofflon can meet the needs of scientific research, pilot test, and commercial production at various stages. Since its foundation, Tofflon has supplied more than 3000 companies across the world.